Pharmaceutical Executive Daily: BioNTech Reports 2026 First Quarter Results
May 05, 07:19 PM
Share
Subscribe
In today's Pharmaceutical Executive Daily, Cellenkos announces FDA clearance of its investigational new drug application for CK0802, BioNTech releases its first quarter 2026 financial results, and Peter Harbin argues that biopharma's longstanding deciling-based sales targeting model is overdue for a fundamental rethink.